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Abstract:  
Orally disintegrating systems have an edge amongst the oral drug delivery systems due to the highest component of 
compliance they enjoy in patients especially the geriatrics and pediatrics. In addition, patients suffering from 
dysphagia, motion sickness, repeated emesis and mental disorders prefer these medications because they cannot 
swallow large quantity of water. Further, drugs exhibiting satisfactory absorption from the oral mucosa or intended 
for immediate pharmacological action can be advantageously formulated in these dosage forms. However, the 
requirements of formulating these dosage forms with mechanical strength sufficient to withstand the rigors of 
handling and capable of disintegrating within a few seconds on contact with saliva are inextricable. Therefore, 
research in developing orally disintegrating systems has been aimed at investigating different excipients as well as 
techniques to meet these challenges. Famciclovir is an antiviral drug used for the treatment of herpes simplex virus 
(HSV), mainly HSV-1 and HSV-2 and varicella zoster virus. It is a BCS class III drug. Hence an orally 
disintegrating tablet formulation of Famciclovir was prepared by wet granulation techniques after incorporating 
superdisintegrants sodium starch glycolate. Six formulations were prepared. The formulation (F3) showed excellent 
in vitro dispersion time and drug release as compared to other formulation. After study of formulations F3 showed 
short dispersion time with maximum drug release in 10 min. It is concluded that fast disintegrating famciclovir 
tablets could be prepared by wet granulation using superdisintegrants. 
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INTRODUCTION:  
ODTs are also called as orodispersible tablets, quick 
disintegrating tablets, mouth dissolving tablets, fast 
disintegrating tablets, fast dissolving tablets, rapid 
dissolving tablets, porous tablets, and rapid melts. 
However, of all the above terms, United States 
pharmacopoeia (USP) approved these dosage forms 
as ODTs. The European Pharmacopoeia has used the 
term orodispersible tablet for tablets that disperses 
readily within 3 minutes in the mouth before 
swallowing. [2] United States Food and Drug 
Administration defined ODT as “A solid dosage form 
containing a medicinal substance or active ingredient 
which disintegrates rapidly usually within a matter of 
seconds when placed upon the tongue.” The 
disintegration time for ODTs generally ranges from 
several seconds to about a minute. [1] 
 
MATERIALS AND METHODS:  
Famciclovir were kindly supplied by Macleods 
Pharma (Daman, India), Sodium starch glycolate 
was supplied by Vishal Chemicals (Mumbai, India) 
and Microcrystalline cellulose Reseach lab Fine 
chem (Mumbai). All the products and materials 
used in this study comply with the pharmaceutical 
and analytical standards, respectively.  
All the research work was carried out at K. B. H. S. 
S. Trust Institute of pharmacy, Malegaon, 
Maharashtra during year 2016-2017. 
 
1. IR Spectrum: Famciclovir was subjected to FT-
IR study (SHIMADZU India) for characterization 
purpose. IR technique is one of the most powerful 
techniques which offer the possibility of chemical 
identification. Famciclovir was mixed with 
potassium bromide (KBr) in 1:100 proportions and 
spectrum was obtained in range of 400-4000 cm-1. 
Potassium bromide was used as a blank while 
running spectrum.  
 
2. U. V. Spectrum: The Famciclovir was subjected 
to UV spectroscopic analysis (Lab India; 3000+) to 
find out the wavelength (λ max) at which it shows 
maximum absorbance. Famciclovir was accurately 
weighed and dissolved in solvent phosphate buffer 
pH 6.8 to obtain stock solution of 1000 μg/ml. This 
solution was then suitably diluted with same solvent 
to get solution of concentration 100 μg/ml and 
further diluted to10 μg/ml. Then the UV spectrum 
of this concentration was recorded over the 
wavelength range 200-400 nm. 
 
3. Calibration Curve by U.V Spectroscopic 
Method  
A. Preparation of stock solution of Famciclovir 
in phosphate buffer pH 6.8:  
a) Preparation of phosphate buffer pH 6.8:  
Weighed quantity of Potassium dihydrogen 
phosphate (KH2PO4), 2.722 g was dissolved in 100 
ml distilled water (DW) and mixed properly. In 
another 100 ml of volumetric flask, solution of 0.2 
M sodium hydroxide was prepared, by dissolving 
0.8g NaOH in 100 ml DW. 50 ml of potassium 
dihydrogen phosphate was taken in 200 ml 
volumetric flask and specified volume of 0.2 N 
NaOH (22.4 ml), was added in it and the volume 
was adjusted with DW to 200 ml [3].   
 
b) Standard stock solution of Famciclovir: 
About 10 mg of drug was accurately weighed and 
transferred to calibrated 10 ml volumetric flask. It 
was dissolved in phosphate buffer pH 6.8 and 
volume was made up to 10 ml with phosphate 
buffer pH 6.8 to obtain a final concentration of 
1000 μg/ml. 
c) Working stock solution: 
This standard stock solution was further diluted to 
get a working standard solution 100 μg/ml, by 
pipetting out 1ml from standard stock and diluting 
it up to 10 ml with phosphate buffer pH 6.8. A 
series of Telmisartan dilutions were made from 
working standard solution, by pipetting out 0.2, 0.6, 
1, 1.4, 1.8 and 2.2 ml respectively into separate 10 
ml volumetric flasks and diluting to volume with 
phosphate buffer pH 6.8 to produce the 
concentrations ranging from 2-22 μg/ml. 
 
4. Drug-Polymers compatibility studies: 
 I. Drug content: The successful formulation of a 
stable and effective solid dosage form depends on 
the careful selection of the excipients, which are 
added to facilitate administration, to promote the 
consistent release and bioavailability of the drug 
and protect it from degradation. API and excipients 
were thoroughly mixed in 1:1 ratio and passed 
through the 60# sieve. The blend was filled in 
transparent glass vials and were closed with gray 
colored rubber stoppers and further sealed with 
aluminum seal. Vials were kept in stability chamber 
at room and aggravated temperature and humidity 
conditions (37±0.5°C, 45±0.5°C temperature and 
75±5%RH for 30 days).  
Similarly, API was also kept at all condition as for 
the samples. Samples were withdrawn for analysis 
within two day of sampling date as per the 
compatibility study and evaluated for FTIR. The 
films were tested for drug content uniformity by 
UV spectrophotometric method. Films were cut 
from three different places from the casted films. 
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Each film was placed in 100 ml volumetric flask 
and dissolved in pH 6.8 phosphate buffer and 
filtered through whatman filter paper. From the 
solution 1 ml was taken and diluted with pH 6.8 
phosphate buffer upto 10 ml, to make final 
concentration of 10μg/ml. The absorbance of the 
solution was measured at 224 nm using UV/visible 
spectrophotometer (R2=0.998). The percentage 
drug content was determined using the standard 
graph and the same procedure was repeated for 
three tablet of each formulation. 
II. Infrared Spectroscopy: A compatibility study 
for Famciclovir was carried out with potential 
formulation excipients to determine possibility of 
any drug-excipients interaction/incompatibility. 
Excipients studied included Avicel pH102, 
Primogel, Starch, Saccharin sodium, Talc, 
Magnesium stearate, (Aerosil) Fumed silicon 
dioxide, Dicalcium phosphate and physical mixture 
of drug with these excipients. These samples were 
subjected to compatibility studies and stored for 30 
days at elevated temperature and humidity 
conditions of 40 ± 2 °C / 75 ± 5 % RH. IR spectra 
of these stored samples were then obtained after 30 
days [4,5,6]. 
 
5. Formulation and Development of ODTs: 
Table no. 1: Composition of Famciclovir ODTs: 
Sr. 
No. 
Name of ingredients F1 
mg 
F2 
mg 
F3 
Mg 
F4 
Mg 
F5 
Mg 
F6 
Mg 
1 Famciclovir 250 250 250 250 250 250 
2 Sodium starch glycolate 
(Primogel) 
110 115 120 125 130 135 
3 Microcrystalline cellulose. (Avicel) 
pH 102 
40 35 30 25 20 15 
4 
 
Starch 40 40 40 40 40 40 
5 Saccharin sodium 25 25 25 25 25 25 
6 Talc 3 3 3 3 3 3 
7 Magnesium stearate 2 2 2 2 2 2 
8 Fumed silicon dioxide (Aerosil) 3 3 3 3 3 3 
9 Dicalcium phosphate 77 77 77 77 77 77 
 Total weight 550 550 550 550 550 550 
 
6. Evaluation of Famciclovir ODTs: [7,8,9] 
The Famciclovir ODTs were evaluated for the 
following properties:  
1. Physical Appearance: The thickness of tablet as a 
dimensional variable was evaluated. The tablet 
thickness was controlled within average value. The 
colour, odours and any other flaws like chips, cracks, 
surface texture, etc. are other important 
morphological characteristics were observed. 
2. Hardness: Tablet hardness is defined as force 
required to crushing the tablet in diametric 
compression test. The hardness was measured with 
Pfizer hardness tester. The tablets were placed 
diametrically between two plungers and the lower 
plunger is kept in contact of tablet to read as zero. 
The upper plunger is forced against a spring by 
turning the screw until tablet fractures. 
3. Friability: 
Twenty tablets were weighed and subjected to 
friability test in Roche friabilator. The pre-weighed 
sample was placed in friabilator which revolves at 25 
rpm for 4 minutes dropping the tablets through a 
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distance of 6 inch with each revolution. This process 
was repeated for all formulations and the percentage 
friability was calculated. 
% loss = Initial wt. of tablets - Final wt. of tablets / 
Initial wt. of tablets x 100 
Where; W1 = Initial weight of tablet  
W2 = weight of tablet after rotation 
4. Weight Variation: For Tablet weighing 250 mg 
or more, not more than two tablets differ from the 
average weight by 10 % deviation. The percent 
deviation in weight variation from average value 
for all formulation of design batches were within 
limit. The weight variation within limits indicates 
uniformity in tablet compression and consequently 
content of drug in a unit. 20 tablets were taken and 
average weight of the tablet was determined. The 
tablets were weighed individually and the weight 
variation was determined.  
5. Thickness and Diameter:  Thickness and 
diameter of tablets was important for uniformity of 
tablet size. The thickness and diameter of tablets 
were determined with the help of Vernier caliper. The 
average diameter and thickness of the tablet was 
calculated. The test passed if none of the individual 
diameter and thickness value deviated by ± 5% of the 
average. 
6. Drug Content: From each batch of prepared 
tablets, ten tablets were collected randomly and 
powdered. A quantity of powder equivalent to 250 
mg was transferred to 250 ml volumetric flask. 50 ml 
of pH 6.8 phosphate buffer was added and then the 
solution was subjected to Sonication for a period of 
about 30 min. The solution was made up to 250 ml 
with 6.8 phosphate buffer. The solution was filtered 
and suitable dilutions were prepared with pH 6.8 
phosphate buffer and then drug content was estimated 
by recording the absorbance at 224 nm by using UV-
visible spectrophotometer. 
7. In vitro Dissolution Studies: 
The dissolution study of the developed drug delivery 
system was planned on the basis of physiological 
condition oral cavity. The media for dissolution is as 
follows:  
 pH 6.8 phosphate buffer  
The volume of media was kept 900 ml to maintain 
sink condition. The apparatus for dissolution used 
was USP-II (Paddle) at 100 rpm. Aliquots were 
withdrawn at 1, 2, 4, 6, 8, 10-minute interval from a 
zone midway between the surface of dissolution 
medium and top of the rotating paddle not less than 1 
cm apart from the suitable replacements with fresh 
medium was also made. Each sample solution was 
filtered through Whatman no. 41 filter paper. The 
absorbance was measured at 224 nm using 
spectrophotometer. 
8. Solubility (S): 
Procedure: 25 mg of sample was accurately 
weighed and transferred into 25 ml volumetric flask 
and volume was made up to the mark with 
methanol. From this 1 ml was taken in 10 ml 
volumetric flask and volume is adjusted up to mark 
with same solvent. The absorbance of the solution 
was measured at 224 nm using appropriate blank. 
The drug content of Famciclovir was calculated 
using calibration curve. 
9. Kinetics of drug release: [10] 
‘In vitro’ dissolution has been recognized as an 
important element in drug development. Under 
certain conditions it can be used as a surrogate for the 
assessment of bioequivalence. Several theories or a 
kinetic model describes drug dissolution from 
immediate and modified release dosage forms.  
 
The quantitative interpretation of the values obtained 
in dissolution assay is facilitated by the usage of 
generic equation that mathematically translates the 
dissolution curve in function of some parameters 
related with the pharmaceutical dosage forms. 
 
In most cases the theoretical concept does not exist 
and some empirical equations have proved to be most 
accurate or appropriate. The kind of drug its 
polymorphic form, crystallinity, particle size, 
solubility and amount in that pharmaceutical dosage 
form can influence the release kinetics. A water 
soluble drug incorporated in a matrix is mainly 
released by diffusion while for low water soluble 
drug the self-erosion of the matrix will be the 
principle release mechanism. 
Zero-Order Kinetics: F=K0t, where F represents 
the fraction of drug released in time t and K0 is the 
zero-order release constant.  
First-Order Kinetics: ln (1-F) = Ktt, where F 
represents the fraction of drug released in time t and 
Kt is the first-order release constant.  
 The model with the highest correlation coefficient 
was considered to be the best fitting one. [12] 
 
10. Accelarated Stability Studies: [11] 
On the basis of In vitro evaluation of all the 
formulation batches for the various parameters, 
formulations were packed in thick aluminum foil and 
stored in ICH certified stability chambers for the 
accelerated stability studies. The tablets were stored 
in the stability chamber at the controlled conditions 
of temperature and relative humidity. The stability of 
the tablets was studied for the duration of  30 days at 
temperature 400C ± 20 C and 75% ± 5% relative 
humidity and room temprature. The tablets was then 
evaluated for various parameters viz. weight 
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variation, thickness,diameter, hardness, friability, 
drug content and release studies. 
 
RESULTS AND DISCUSSION: 
1. IR Spectrum:  
For characterization of pure Famciclovir FTIR 
studies were carried out. The observed and reported 
characteristic peaks of functional group have been 
shown in table 8.1 and IR spectrum is shown in 
(Fig.1). 
 
Fig.no. 1: IR Spectrum of Famciclovir (pure drug) 
 
Table no. 2: Reported and observed principal peaks of Famciclovir in IR 
Functional group Characteristics Observation 
C-H (Stretching) 3000-2800 2947 
Ester 1750-1730 1732 
C=C 1680-1600 1654 
N-H (bending) 1640-1550 1581 
C-N (Amine) 1300-1000 1219 
 
2. U. V. Spectrum:  
Famciclovir shown absorbance at 224 nm in phosphate buffer solution pH 6.8 (Fig.8.2). While reported λ max of 
drug is 224 nm. 
 
 
Fig.no. 2: UV spectrum of Famciclovir in Phosphate buffer pH 6.8 
 
3. Calibration Curve by UV Spectroscopic Method:  
1. Calibration curve in phosphate buffer pH 6.8:  
A linear relationship was obtained in Beer-Lamberts plot of Famciclovir (y =0.0965x+0.0139, R2=0.998). The 
calibration data is given in Table 8.2 and graph obtained after plotting absorbance (y) vs. concentration (x) is shown 
in Fig.3. 
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Fig.no. 3: Calibration curve of Famciclovir in PBS 6.8 by UV 
 
Spectroscopic method: 
Table no. 3: Calibration data of Famciclovir in PBS 6.8 by UV spectroscopic method 
Sr.No Concentration Absorbance 
1 0 0 
2 2 0.185 
3 4 0.355 
4 6 0.546 
5 8 0.755 
6 10 0.971 
 
4. Drug-Polymers compatibility study:  
A) Infrared Spectroscopy: 
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Fig. no.4: IR spectrum of Famciclovir with Avicel pH102 
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Fig. no.5: IR spectrum of Famciclovir with Primogel 
650750850950105011501250135014501550165017501850195020502150225023502450255026502750285029503050315032503350345035503650375038503950
cm-1
60
62
64
66
68
70
72
74
76
78
80
82
84
86
88
90
92
94
96
98
100
102
104
%T
3
6
7
2
.4
7
3
3
3
2
.9
9
3
1
6
3
.2
6
2
9
1
8
.3
0 2
8
5
0
.7
9
1
7
2
8
.2
2
1
6
5
3
.0
0
1
6
1
4
.4
2
1
5
7
9
.7
0
1
5
3
9
.2
0
1
4
6
3
.9
7
1
3
6
9
.4
6 1
3
0
3
.8
8
1
2
1
1
.3
0
1
0
2
0
.3
4
8
3
5
.1
8
8
0
0
.4
6
7
2
1
.3
8
6
6
9
.3
0
Smoothing
Samples by Momin Azizurrahman Pharmacy college Malegaon 
 
Fig. no.6: IR Spectrum of Famciclovir and mixture of Excipients (Avicel, Primogel (S.G.S), Starch, 
Saccharine sodium, Talc, Magnesium stearate, Aerosil, Dicalcium phosphate.) 
The Drug-excipients interaction study had shown no interaction between Famciclovir and selected polymers as there 
was no significant shift of peaks in IR spectrum. Also the characteristic peaks of drug Famciclovir were observed in 
IR spectrum of drug-excipients and in physical mixture sample. From these IR spectra, it was concluded that the 
selected excipients were compatible with drug Famciclovir. 
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5. Evaluation of flow properties of powder blends: 
The characterization of flow properties of powder blends is important in tablet compression. The powder blends 
with good flow properties gives uniform die fill and consequently it gives the uniform tablet weight. The values are 
given in table no. 4. 
 
Table 4: Flow properties of powder 
Formulation 
Bulk Density 
(gm/cm2) 
Tapped Density 
(gm/cm2) 
Carr’s Index 
(%) 
Hausner 
Ratio 
Angle of 
Repose (0) 
F1 0.5412± 0.013 0.6601± 0.062 21.4366± 1.831 1.3472± 0.238 27.64±  1.224 
F2 0.4512± 0.013 0.5265± 0.088 25.8133± 1.626 1.5493± 0.304 28.56±  0.871 
F3 0.4135± 0.024 0.5152± 0.051 38.1650± 0.816 1.2727± 0.125 
19.45.15±  
1.115 
F4 0.4662± 0.015 0.5033± 0.038 26.9250± 0.880 
1.3723± 
0.0890 
26.42±  0.733 
F5 0.5281± 0.031 0.4907± 0.069 31.8207± 1.201 
1.5111± 
0.2987 
28..17±  
1.426 
F6 0.4171± 0.01 0.4920± 0.032 16.9122± 0.816 1.256± 0.146 
23.15±  
2.849 
 
1. Angle of repose   
The angle of repose can be correlated with type of 
flow of powder. The angle of repose below 25º 
indicates excellent flow properties. The angle of 
repose was found to be within the range of 19º to 28º 
indicating good flow properties. 
2. Bulk density  
The bulk density of powder is important parameter in 
the compressibility of the powder. The bulk density 
was between 0.41 to 0.54gm/cm2. 
3. Tapped density  
The tapped density of powder is important 
parameters in the compressibility of the powder. The 
tapped density was found to be 0.49 to 0.66 gm/cm2. 
 
4. Carr’s index 
The Carr’s index is indicator of compressibility. The 
value below 21 % shows good compressibility. It was 
found to be 16 to 38 %. indicating good 
compressibility. 
5. Hausner’s ratio  
The Hausner ratio is another parameter indicating the 
flow properties. The value of ratio below 1.25 
indicates good flow while above 1.25 indicates the 
poor flow. It was found to be 1.25 to 1.54 indicating 
poor flow ability. 
6. Evaluation of Tablets: 
The tablet parameter like weight variation, Hardness, 
thickness, diameter, friability, and drug content were 
evaluated and values are given in table no.5. 
Table 5: Evaluation of Tablets 
Formulation 
Weight 
variation 
mg±SD 
Hardness 
(Kg/cm2) 
±SD 
Thickness 
(mm) ±SD 
Diameter 
(mm) ±SD 
Friability 
(%) 
Drug content 
(%) 
F1 549.25± .153  3.6±0.2 4.93 ± 0.21 11.26 ± 0.15  0.2811 96.26± 0.230 
F2 552.35± .758 3.6±0.26 4.72 ± 0.06 11.31 ± 0.43 0.1696 98.62± 3.602 
F3 551.20± .125 3.4± 0.21 4.05 ± 0.12 11.23 ± 0.13 0.4121 96.54±1.325 
F4 548.95 ± 2.064 3.5± 0.2 4.61 ± 0.06 11.29 ± 0.15 0.1801 97.98±1.876 
F5 549.5± 2.212 
3.6±  
0.26 
4.58 ± 0.06 11.42 ± 0.18 0.3032 94.67±0.933 
F6 552.65± 1.094 
3.7±  
0.25 
4.66 ± 0.31 11.27 ± 0.12 0.3751 99.85±1.445 
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1. 
Weight variation 
The weight variation of the formulation F1 to F6 
ranged from 548.95 to 552.35 mg and percentage 
deviation ranged from 1.09 to 3.15 %. The 
percentage deviations of the tablets have to be 
specific, and they should not differ ± 5% according 
to IP specification. 
 
2. Hardness and Friability 
The Hardness of the formulation F1 to F6 ranged 
from 3.4 to 3.7 Kg/cm2. However, hardness alone 
cannot be considered as absolute indicator of the 
tablet strength. Hence another parameter measured 
was the friability of the tablets. The friability of the 
tablets was found to be less than 1 % which was 
considered within the limit [USP]. The measure of 
these two parameters gives the strength of the tablets 
during handling, packaging, shipping etc. 
3. Thickness and Diameter 
The percentage deviation of thickness and diameter 
of the formulation F1 to F6 ranged from 0.05 to 0.21 
and 0.12 to 0.43 respectively. These parameter of the 
tablets have to be specific, and they should not differ 
± 5% of the average value. The tablet evaluated 
showed within the limit and thus passes the test. 
4. Drug content 
The uniformity in the drug content is an important 
measure. It gives the percentage of drug present per 
unit dosage form. The content uniformity was found 
within 94.62 to 99.85 % of the 250 mg of 
Famciclovir. Hence the tablets prepared showed good 
content uniformity. 
 
Table no. 6. Result of disintegration time, wetting time of Orally Disintegrating Tablets. 
 
 
Batches 
Parameter 
Disintegration time (sec) Wetting time (sec) 
1 95.53± 2.00 68.00 ± .1145 
2 120.25± 3.00 75.00 ± 2.00 
3 175.00±1.00 125.45±3.56 
4 119.22± 1.02 98.33 ± 2.12 
5 165.00 ± 2.08 85.33 ± 2.89 
6 90.51± 0.48 65.45 ± 0.67 
 
4. In- vitro drug release studies:  
Table no.7: Percent cumulative drug from formulation F1 to F6 
Time 
[mint] 
 
% Cumulative Drug Release 
 Batch Code 
 F1 F2 F3 F4 F5 F6 
0 0 0 0 0 0 0 
1 34.56 44.06 38.66 36.50 39.09 43.83 
2 44.52 63.89 43.91 44.04 46.72 73.82 
4 60.34 72.66 57.40 60.63 57.13 78.72 
6 73.28 81.42 70.97 72.70 70.98 82.10 
8 76.62 84.38 84.75 79.51 81.74 94.21 
10 82.30 93.92 91.98 85.27 87.59 98.14 
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% cumulative drug releases of all batches:  
 
 
 
 
 
 
 
 
 
 
 
Fig.no. 7. % Cumulative drug release of all batches 
 
5. Kinetics of drug release:  
The value of coefficient of regression for different models of optimized formulation is given in table. no. 9. The 
coefficient of regression value was found to be highest for First order model and hence the release mechanism was 
found to follow First order kinetics. 
Zero order equation: 
 
Fig. no. 8.  Zero order kinetics model of formulation F1-F6 
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First order equation: 
 
Fig. no.9.  First order kinetics model of formulation F1-F6 
8. Curve Fitting analysis for different 
formulation: 
The in-vitro release studies data was quantified to 
determine the release mechanism, to fit various 
mathematical models and to determine the best fit 
model for formulation. The parameters like 
regression co-efficient (R2) were calculated in the set 
of data, the model showing highest values of R2 was 
considered as best fit model. 
The kinetic data of orally disintegrating tablets 
formulation are shown in table no8.11. when the data 
were plotted according to zero order equation and 
first order equation showed correlation coefficient 
values between 0.7039 -0.8855and 0.9407 -0.9806 
respectively. Hence, the results revealed that all the 
orally disintegratings tablets formulation release the 
drug by First order kinetics as R2 close to one. 
 
Table no.9: Regression coefficient (r2) different kinetic models of formulation F1 to F6. 
Formulation Regression 
Zero order First order 
F1 0.8461 0.9616 
F2 0.7323 0.9413 
F3 0.7039 0.9407 
F4 0.8461 0.9806 
F5 0.8516 0.9776 
F6 0.8855 0.9704 
 
9. Accelerated stability studies:  
The results of stability study are as follows. 
1)  There was no change in the physical appearance of the tablet. 
2)  The total drug content was 
Table no.9. Stability study 
Formulation  Drug content before 
stability study 
Drug content after stability 
study 
F6 99.62 % 99.85 % 
       
3)   The release pattern of the drug was studied by dissolution studies in same         way as done previously. The 
results obtained were compared with the previous data, the comparative data shown in graph is as follow. 
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Fig: no.10. In vitro dissolution profile for stability study 
 
From the graph it is observed that the drug release 
pattern after stability (F6) study was nearly same as 
before stability (F6) with little difference. 
 
Thus the formulation showed the characteristics of 
stable dosage form with no change in the 
physiochemical characteristics and release pattern. 
 
CONCLUSION: 
The Orally Disintegrating Tablets have potential 
advantages over conventional dosage forms, with 
their improved patient compliance; convenience 
bioavailability and rapid onset of action had drawn 
the attention of many manufacturers over a decade. 
The preparation process of wet granulation tablets 
includes granule formation of all the excipients 
before compression, resulting the increase in the 
solubility due to the reduction in the effective particle 
size of the drug following increase in the wetting of 
drug particle by the excipients and improved 
dissolution of drugs by wet granulation.  
 
In conclusion, overall results suggest that the ODTs 
of Famciclovir (F6) shows best results as compared 
to other formulations in terms of percent drug release, 
compressibility index, and hardness and 
disintegration time. This work concluded that F6 was 
found best formulation because it is having good 
disintegration time (90.51±0.48) and dissolution 
responses (98.14 %) in 10 mints as compared to other 
concentration of superdisintegrants. Thus, ODTs may 
be developed for Famciclovir, for quick onset of 
action without need of water for swallowing or 
administration, however further studies are 
investigations are needed to confirm the in vitro 
efficiency and for the development of ODT of 
Famciclovir. This work gives idea about the selection 
and compatibility of the superdisintegrants with 
respect to the drug. 
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